Status:
UNKNOWN
Efficacy and Safety of Adjunctive Cilostazol in Acute Myocardial Infarction Patients
Lead Sponsor:
Korea University Guro Hospital
Conditions:
Acute Myocardial Infarction
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Current antiplatelet therapy in acute coronary syndrome have a focus on the dual antiplatelet therapy including aspirin and clopidogrel. However, the patient's drug resistance of aspirin and clopidogr...
Detailed Description
Drug-eluting stents (DES) have drastically changed the landscape of percutaneous coronary intervention (PCI), with significant reductions in the angiographic restenosis rate and need for repeated reva...
Eligibility Criteria
Inclusion
- Acute Myocardial Infarction Undergoing Primary percutaneous coronary intervention.
Exclusion
- The patient has a known hypersensitivity or contraindication to any of the following medications: Heparin, Aspirin, Clopidogrel, Cilostazol
- Uncontrolled hypertension
- History of bleeding diathesis or known coagulopathy (including heparin-induced thrombocytopenia), or refuses blood transfusions.
- Baseline hemogram with Hb\<10g/dL or PLT count\<100,000/μL
- Patients already taking warfarin, cilostazol or any other type of anti-platelet agents except aspirin and clopidogrel
- Gastrointestinal or genitourinary bleeding within the prior 3 months, or major surgery within 2 months.
- Pregnancy
Key Trial Info
Start Date :
July 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2022
Estimated Enrollment :
951 Patients enrolled
Trial Details
Trial ID
NCT01261832
Start Date
July 1 2011
End Date
March 1 2022
Last Update
February 20 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Korea University Guro Hospital
Seoul, South Korea